纵横研报
Ticker Detail

688621.SHG

¥58+14.44% 阳光诺和 Drug Manufacturers - Specialty & Generic
00Reports China 医疗健康
Beijing Sun Novo Pharmaceutical Research Co Ltd
医疗健康 · 专科与仿制药

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; oncology, metabolic diseases, respiratory tract drug delivery and topical preparation platforms; polypeptide and other drug molecular design and development platform; genotoxic impurity detection platform; technology platform for slow and controlled release preparations; drug synthesis platform; and synthesis technology platform. It also offers SMO, clinical quality management, data management and statistical analysis, project management, test center, clinical research center, clinical trials, TMFDocument management, quality control, Medical Writing, medical monitoring, and pharmacovigilance services; and registration-related services for chemical drugs, biological products, and medical device products. In addition, the company operates a quantitative pharmacology platform that uses technology in pharmacokinetics, pharmacodynamics, body function, disease mechanism and test process, and other information for quantitative research; and mass spectrometry, immunological analysis, cell biology, and molecular biology platforms that provide biological analysis services for large and small molecular drugs, as well as operates as a Contract Research Organization for Professional Peptide Drug Research and Development. The company offers clinical research technology services to pharmaceutical companies and new drug research institutions. Beijing Sun-Novo Pharmaceutical Research Co., Ltd. was founded in 2009 and is based in Beijing, China.

MARKET 市值 5.78B CNY PE 29.2x 52W ¥46.51 – ¥86.18 EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG 营收 YoY -14.6% ROE 17.5% 营业利润率 7.6% 净利润率 16.4%
ANALYST 股息率 0.38%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制